BAY-985 is a potent, selective, and orally bioavailable inhibitor of KRAS G12D, a mutated form of the KRAS protein implicated in various cancers, including lung and pancreatic cancer. It is primarily used in medical research for oncology, particularly to study its ability to disrupt signaling pathways that promote tumor growth and proliferation in KRAS-mutant cancers. Researchers utilize BAY-985 in preclinical studies to evaluate its efficacy as a potential therapeutic agent, focusing on inhibiting overactive molecular targets in cancer cells. It is also investigated for combination therapies to enhance the effectiveness of other anticancer drugs and develop targeted treatments that minimize side effects while maximizing outcomes.